TY - JOUR AU - Nookeu, Pornboonya AU - Angkasekwinai, Nasikarn AU - Foongladda, Suporn AU - Phoompoung, Pakpoom T1 - Clinical Characteristics and Treatment Outcomes for Patients Infected with Mycobacterium haemophilum T2 - Emerging Infectious Disease journal PY - 2019 VL - 25 IS - 9 SP - 1648 SN - 1080-6059 AB - Mycobacterium haemophilum is a nontuberculous mycobacterium that can infect immunocompromised patients. Because of special conditions required for its culture, this bacterium is rarely reported and there are scarce data for long-term outcomes. We conducted a retrospective study at Siriraj Hospital, Bangkok, Thailand, during January 2012–September 2017. We studied 21 patients for which HIV infection was the most common concurrent condition. The most common organ involvement was skin and soft tissue (60%). Combination therapy with macrolides and fluoroquinolones resulted in a 60% cure rate for cutaneous infection; adding rifampin as a third drug for more severe cases resulted in modest (66%) cure rate. Efficacy of medical therapy in cutaneous, musculoskeletal, and ocular diseases was 80%, 50%, and 50%, respectively. All patients with central nervous system involvement showed treatment failures. Infections with M. haemophilum in HIV-infected patients were more likely to have central nervous system involvement and tended to have disseminated infections and less favorable outcomes. KW - Mycobacterium haemophilum KW - bacteria KW - tuberculosis and other mycobacteria KW - nontuberculous mycobacterium KW - clinical characteristics KW - treatment outcomes KW - infection KW - Bangkok KW - Thailand KW - nontuberculous mycobacteria DO - 10.3201/eid2509.190430 UR - https://wwwnc.cdc.gov/eid/article/25/9/19-0430_article ER - End of Reference